Comparative Pharmacology
Head-to-head clinical analysis: QTERNMET XR versus RIOMET ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QTERNMET XR versus RIOMET ER.
QTERNMET XR vs RIOMET ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Qternmet XR is a combination of saxagliptin (a DPP-4 inhibitor) and metformin (a biguanide). Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, enhancing glucose-dependent insulin secretion and suppressing glucagon release. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Adults: 500 mg orally once daily with the evening meal, increase by 500 mg every 1-2 weeks up to a maximum of 2000 mg once daily. For extended-release (XR) formulation, titrate from 500 mg to 2000 mg once daily.
Oral, 500 mg once daily, increase by 500 mg weekly to maximum 2000 mg once daily.
None Documented
None Documented
Terminal half-life: 4–6 hours; clinically relevant for dosing interval (every 6–8 hours) and steady-state achievement within 24 hours.
Terminal elimination half-life is approximately 6.2 hours in patients with normal renal function; prolonged to up to 17.6 hours in renal impairment (eGFR <30 mL/min).
Renal: 90% unchanged via glomerular filtration and tubular secretion; fecal: 10%.
Renal elimination of unchanged drug accounts for approximately 90% of an absorbed dose; fecal excretion is minimal (<5%).
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic